These Stocks are Riding Some of the Hottest Narratives on Wall Street
2026-05-19 11:30:35 ET
Denver, Colorado ( www.247marketnews.com ) – Here are today’s most compelling market narratives.
Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store
NeOnc Technologies Gains Growing Institutional Support and “Buy” ratings Ahead Of Key Brain Cancer Clinical Milestones
NeOnc Technologies (NASDAQ: NTHI ), a clinical-stage biotechnology company focused on central nervous system (CNS) cancers, is beginning to attract broader Wall Street attention as investors look for differentiated oncology platforms with near-term clinical catalysts. The company is advancing proprietary intranasal drug delivery technologies designed to bypass the blood-brain barrier, one of the most difficult challenges in neuro-oncology and brain cancer treatment.
Its lead candidate, NEO100, is currently being evaluated in a fully enrolled Phase 2a trial targeting aggressive brain tumors including glioblastoma, with interim data expected in the near term. The company is also developing NEO212, a hybrid therapeutic candidate with potential applications across multiple CNS malignancies and neurological conditions. As brain cancer therapies continue to represent a major unmet medical need, investors are increasingly watching companies developing novel delivery systems and targeted CNS approaches.
Maxim Group initiated coverage on NeOnc with a “Buy” rating and a $20.00 price target , while Alliance Global Partners with a “Buy (Speculative) rating and a $13.00/share price target”, highlighting what the firms see as significant upside potential relative to the company’s current trading price. BTIG Research also recently launched coverage with a “Buy” rating and a $15.00 price target , reflecting increasing analyst interest in NeOnc’s differentiated CNS-focused platform.
Wall Street firms have recently initiated coverage on the company. Maxim Group launched coverage with a “Buy” rating and a $20.00 price target , while Alliance Global Partners initiated with a “Buy (Speculative) rating and a $13.00/share price target”. BTIG Research also began coverage with a “Buy” rating and a $15.00 price target , reflecting growing analyst attention on NeOnc’s CNS-focused platform and upcoming clinical milestones.
Investor confidence has also been reinforced by continued insider accumulation. Amir Heshmatpour, the company’s CEO, Chairman, and President, has reportedly purchased more than $500,000 worth of shares recently, with cumulative insider buying approaching $1 million over the past year. Institutional ownership has also expanded, with firms including Bank of America, State Street Corp, Barclays PLC, Westmount Partners, and Foundations Investment Advisors increasing positions according to recent filings.
Amesite Lands Major AI Healthcare Enterprise Deployment
Amesite (NASDAQ:AMST) announced what it described as its largest deployment to date for its AI-native NurseMagic™ platform, securing a new enterprise customer representing an approximately 2,700-patient census. The company’s technology is focused on reducing documentation burdens in non-acute healthcare environments, a market increasingly embracing AI-driven workflow automation.
According to the company, NurseMagic™ can reduce documentation time from approximately 20 minutes to 20 seconds, helping caregivers streamline operations while integrating with EMR and electronic visit verification systems. Amesite believes the deployment validates its “AI-first” infrastructure strategy and demonstrates scalability across complex enterprise healthcare organizations.
CEO Dr. Ann Marie Sastry stated the deployment validates the architecture’s ability to support layered permissions, integrations, and custom documentation without extensive consulting costs often associated with legacy systems. Management also highlighted an approximately 18% reduction in operating spend over the last six quarters while continuing to expand its customer base.
The company additionally noted that sales and marketing activity is generating roughly 4,200 web visits per day alongside growing inbound interest from providers seeking AI-native alternatives to legacy healthcare software systems. With healthcare AI becoming one of the fastest-growing sectors in technology, smaller emerging companies with enterprise traction are increasingly drawing speculative investor interest.
MetaVia Advances Obesity and Metabolic Disease Pipeline Ahead of ADA 2026
MetaVia (NASDAQ:MTVA), a clinical-stage biotechnology company focused on cardiometabolic disease treatments, announced that three late-breaking abstracts have been accepted for presentation at the American Diabetes Association’s 2026 Scientific Sessions. The presentations will highlight DA-1726, the company’s GLP-1/glucagon dual agonist obesity treatment candidate, as well as vanoglipel, its GPR119 agonist targeting metabolic disease and MASH.
The obesity drug sector has become one of the hottest investment themes in biotech, fueled by the commercial success of GLP-1 therapies. MetaVia’s DA-1726 is designed as a dual agonist targeting both GLP-1 and glucagon receptors, with the goal of promoting weight loss through appetite reduction and increased energy expenditure. The company stated that Phase 1 data demonstrated potential for significant weight loss, glucose control, and waist circumference reduction.
Management believes the ADA conference presentations help validate the strength of the company’s broader cardiometabolic pipeline. MetaVia also emphasized that vanoglipel demonstrated encouraging preclinical activity in metabolic dysfunction-associated steatohepatitis (MASH) and Type 2 diabetes models, including improvements in liver inflammation, fibrosis, glucose metabolism, and weight reduction.
As investor capital continues flowing into obesity and metabolic disease therapies, companies with differentiated mechanisms and upcoming clinical catalysts remain under close market scrutiny, particularly those developing alternatives or complementary approaches to existing GLP-1 therapies.
Agilysys Delivers 17th Consecutive Record Revenue Quarter
Agilysys (NASDAQ:AGYS), a hospitality software solutions provider, reported its 17th consecutive record revenue quarter, posting quarterly revenue of $82.9 million and full-year revenue of $319.3 million for fiscal 2026.
The company’s recurring revenue continues expanding rapidly, with subscription revenue growing more than 30% year-over-year during the fiscal year. Agilysys also reported record adjusted EBITDA and free cash flow, highlighting increasing operational leverage as recurring SaaS revenue becomes a larger percentage of the company’s overall business mix.
Management pointed to growing momentum surrounding AI-native hospitality software solutions and highlighted recent development of new AI-driven products including revenue intelligence and CRS modules. The company believes AI integration is helping accelerate product differentiation and operating efficiency across the organization.
Agilysys projected fiscal 2027 revenue between $365 million and $370 million alongside another year of at least 30% subscription revenue growth. Investors continue closely monitoring software companies successfully integrating AI functionality into established recurring revenue business models.
InMed Pharmaceuticals & Mentari Therapeutics Merge to Target Massive Migraine Market
InMed Pharmaceuticals (NASDAQ:INM) announced a merger agreement with privately held Mentari Therapeutics, creating a combined company focused on next-generation migraine prevention therapies.
The transaction is accompanied by an oversubscribed $290 million private placement involving major healthcare investment firms including Janus Henderson Investors, Wellington Management, Vivo Capital, Perceptive Advisors, RTW Investments, and others. The financing is expected to fund operations through 2028 and support development of Mentari’s lead migraine therapies.
Mentari’s pipeline includes MT-001, an anti-PACAP monoclonal antibody, and MT-002, a potentially first-in-class anti-CGRP/anti-PACAP bispecific antibody. The programs target migraine pathways believed to complement existing CGRP-targeted therapies, potentially addressing patients who continue experiencing migraines despite current treatments.
Migraine therapeutics remain one of the largest neurological markets globally, affecting more than one billion people worldwide. Investors continue closely watching companies pursuing differentiated mechanisms in neurology and pain management, particularly those supported by substantial institutional financing.
Co-Diagnostics Develops Ebola Assay Strategy Amid Global Outbreak Concerns
Co-Diagnostics (NASDAQ:CODX) announced completion of an assay development strategy targeting the Bundibugyo virus strain currently associated with Ebola outbreaks in the Democratic Republic of Congo and Uganda.
The announcement followed heightened global health alerts from both the World Health Organization and the CDC related to Ebola monitoring and traveler screening measures. Co-Diagnostics stated its proprietary Co-Dx PCR platform was specifically designed to support decentralized diagnostics and rapid outbreak response capabilities.
Management emphasized the importance of real-time situational awareness and decentralized molecular testing infrastructure in identifying and containing infectious disease outbreaks. The company believes lessons learned during the COVID-19 pandemic continue driving demand for rapid-response diagnostic platforms.
While the company’s PCR platform remains subject to regulatory review and is not currently available for sale, investors continue monitoring diagnostic technology developers positioned to respond quickly to emerging global public health threats.
Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store.
Sources and Links
· NeOnc Technologies https://www.neonctech.com/
· Amesite https://www.amesite.com/
· MetaVia https://www.metaviatx.com/
· Agilysys https://www.agilysys.com/ https://www.businesswire.com/news/home/20260518224140/en/
· InMed Pharmaceuticals https://www.prnewswire.com/news-releases/inmed-pharmaceuticals--mentari-therapeutics-announce-merger-to-advance-migraine-prevention-therapies-302776112.html
https://www.inmedpharma.com/
· Co-Diagnostics https://www.prnewswire.com/news-releases/co-diagnostics-develops-ebola-assay-strategy-following-recent-global-outbreak-alert-302775926.html
https://www.codiagnostics.com/
Top of Form
Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor. For the full disclosure, please visit: https://go.247marketnews.com/nthi-disclosure/
For further information, please visit 247marketnews.com .
CONTACT:
24/7 Market News
Editor@247marketnews.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
NASDAQ:NTHI, NASDAQ:AMST, NASDAQ:MTVA, NASDAQ:AGYS, NASDAQ:INM, NASDAQ:CODX
, , , , ,
For further details see:
These Stocks are Riding Some of the Hottest Narratives on Wall Street
NASDAQ: INM
INM Trading
123.81% G/L:
$1.555 Last:
73,877,530 Volume:
$1.79 Open:
